Searched for: person:mdk230
in-biosketch:true
A Phase 0, Window of Opportunity Study of Parasympathetic Stimulation with Bethanechol in Localized Pancreatic Adenocarcinoma Prior to Surgery
White, Ruth A; Mezzano-Robinson, Valeria; Shi, Qiongyu; Kuriakose, Nadine; Schrope, Beth; Kluger, Michael D; Sugahara, Kazuki; Chabot, John; Manji, Gulam; Oberstein, Paul; Remotti, Helen; Wang, Timothy C; Bates, Susan E
BACKGROUND:The parasympathetic branch of the autonomic nervous system has shown tumor-suppressive effects in preclinical models of pancreatic adenocarcinoma (PDAC) by inhibiting cancer stem cells and suppressing inflammatory cytokine production. Based on these findings, we hypothesized that bethanechol, an FDA-approved parasympathomimetic agent targeting muscarinic receptors, could enhance treatment efficacy in PDAC. METHODS:We conducted a Phase 0/window of opportunity study evaluating short term parasympathetic activation with fixed dose bethanechol (100 mg twice daily) in subjects with resectable or borderline resectable PDAC prior to surgery. The primary endpoint was change in cell proliferation by Ki-67 expression compared to stage matched controls. Secondary endpoints included tissue expression of stem cell markers (CD44), infiltrating immune cells (CD8a, Granzyme B, and CD68), and changes in circulating inflammatory cytokine concentrations. RESULTS:Seventeen patients were enrolled with 13 eligible for analysis of endpoints. Median age was 74 (59-86), 6 female (46%), all ECOG 0-1 and median duration of treatment was 8 days (7-13). R0 resections were achieved in 9 patients (69%). There was no difference in Ki67 and CD44 tissue biomarkers between bethanechol-treated and control samples. Decreased numbers of Granzyme B-expressing cells were seen in bethanechol-treated tissues. Bethanechol treatment was associated with suppression of circulating IL-18. The most common treatment related adverse events (TRAE) were hot flashes (30.7%), urinary frequency (15.4%), increased salivation (15.4%), hyperhidrosis (7.7%), and nausea (7.7%). There were no Grade 3 or higher adverse effects. No surgical complications were attributed to bethanechol treatment. CONCLUSION/CONCLUSIONS:Bethanechol 100 mg twice daily is well tolerated in patients with PDAC in this small phase 0/window of opportunity study (NCT03572283). Bethanechol treatment was associated with decreased Granzyme B positive cells and decreased circulating IL-18 consistent with an anti-inflammatory role for parasympathetic muscarinic signaling in PDAC.
PMID: 40448309
ISSN: 1549-490x
CID: 5854602
Factors Associated With Aborted Whipple Procedures for Periampullary Carcinoma: A Multicenter Case-Control Study by the SAR Pancreatic Ductal Adenocarcinoma Disease Focus Panel
van der Pol, Christian B; Sabil, Mustafa; Komar, Madeline; Ruo, Leyo; Silva, Jéssyca; Mbuagbaw, Lawrence; Liau, Joy; Nguyen, Rina; Chung, Andrew; Hu, Zoe; Nanji, Sulaiman; Luk, Lyndon; Kluger, Michael D; Chu, Linda; Zaheer, Atif; Ibad, Hamza A; He, Jin; Huang, Chenchan; Le, Linda; Hewitt, Brock; Wang, Zhen Jane; Zins, Marc; Rana, Sumit; Angliviel, Benjamin; Depetris, Jena N; Galgano, Samuel J; Bolan, Candice W; Soloff, Erik; Arif-Tiwari, Hina; Kambadakone, Avinash; Do, Richard Kinh Gian; Hecht, Elizabeth M; ,
PMID: 40042924
ISSN: 1546-3141
CID: 5814242
Author Correction: Tumour-selective activity of RAS-GTP inhibition in pancreatic cancer
Wasko, Urszula N; Jiang, Jingjing; Dalton, Tanner C; Curiel-Garcia, Alvaro; Edwards, A Cole; Wang, Yingyun; Lee, Bianca; Orlen, Margo; Tian, Sha; Stalnecker, Clint A; Drizyte-Miller, Kristina; Menard, Marie; Dilly, Julien; Sastra, Stephen A; Palermo, Carmine F; Hasselluhn, Marie C; Decker-Farrell, Amanda R; Chang, Stephanie; Jiang, Lingyan; Wei, Xing; Yang, Yu C; Helland, Ciara; Courtney, Haley; Gindin, Yevgeniy; Muonio, Karl; Zhao, Ruiping; Kemp, Samantha B; Clendenin, Cynthia; Sor, Rina; Vostrejs, William P; Hibshman, Priya S; Amparo, Amber M; Hennessey, Connor; Rees, Matthew G; Ronan, Melissa M; Roth, Jennifer A; Brodbeck, Jens; Tomassoni, Lorenzo; Bakir, Basil; Socci, Nicholas D; Herring, Laura E; Barker, Natalie K; Wang, Junning; Cleary, James M; Wolpin, Brian M; Chabot, John A; Kluger, Michael D; Manji, Gulam A; Tsai, Kenneth Y; Sekulic, Miroslav; Lagana, Stephen M; Califano, Andrea; Quintana, Elsa; Wang, Zhengping; Smith, Jacqueline A M; Holderfield, Matthew; Wildes, David; Lowe, Scott W; Badgley, Michael A; Aguirre, Andrew J; Vonderheide, Robert H; Stanger, Ben Z; Baslan, Timour; Der, Channing J; Singh, Mallika; Olive, Kenneth P
PMID: 39533066
ISSN: 1476-4687
CID: 5787002
Protein biomarkers and alternatively methylated cell-free DNA detect early stage pancreatic cancer
Ben-Ami, Roni; Wang, Qiao-Li; Zhang, Jinming; Supplee, Julianna G; Fahrmann, Johannes F; Lehmann-Werman, Roni; Brais, Lauren K; Nowak, Jonathan; Yuan, Chen; Loftus, Maureen; Babic, Ana; Irajizad, Ehsan; Davidi, Tal; Zick, Aviad; Hubert, Ayala; Neiman, Daniel; Piyanzin, Sheina; Gal-Rosenberg, Ofer; Horn, Amit; Shemer, Ruth; Glaser, Benjamin; Boos, Natalia; Jajoo, Kunal; Lee, Linda; Clancy, Thomas E; Rubinson, Douglas A; Ng, Kimmie; Chabot, John A; Kastrinos, Fay; Kluger, Michael; Aguirre, Andrew J; Jänne, Pasi A; Bardeesy, Nabeel; Stanger, Ben; O'Hara, Mark H; Till, Jacob; Maitra, Anirban; Carpenter, Erica L; Bullock, Andrea J; Genkinger, Jeanine; Hanash, Samir M; Paweletz, Cloud P; Dor, Yuval; Wolpin, Brian M
OBJECTIVE:Pancreatic ductal adenocarcinoma (PDAC) is commonly diagnosed at an advanced stage. Liquid biopsy approaches may facilitate detection of early stage PDAC when curative treatments can be employed. DESIGN:To assess circulating marker discrimination in training, testing and validation patient cohorts (total n=426 patients), plasma markers were measured among PDAC cases and patients with chronic pancreatitis, colorectal cancer (CRC), and healthy controls. Using CA19-9 as an anchor marker, measurements were made of two protein markers (TIMP1, LRG1) and cell-free DNA (cfDNA) pancreas-specific methylation at 9 loci encompassing 61 CpG sites. RESULTS:Comparative methylome analysis identified nine loci that were differentially methylated in exocrine pancreas DNA. In the training set (n=124 patients), cfDNA methylation markers distinguished PDAC from healthy and CRC controls. In the testing set of 86 early stage PDAC and 86 matched healthy controls, CA19-9 had an area under the receiver operating characteristic curve (AUC) of 0.88 (95% CI 0.83 to 0.94), which was increased by adding TIMP1 (AUC 0.92; 95% CI 0.88 to 0.96; p=0.06), LRG1 (AUC 0.92; 95% CI 0.88 to 0.96; p=0.02) or exocrine pancreas-specific cfDNA methylation markers at nine loci (AUC 0.92; 95% CI 0.88 to 0.96; p=0.02). In the validation set of 40 early stage PDAC and 40 matched healthy controls, a combined panel including CA19-9, TIMP1 and a 9-loci cfDNA methylation panel had greater discrimination (AUC 0.86, 95% CI 0.77 to 0.95) than CA19-9 alone (AUC 0.82; 95% CI 0.72 to 0.92). CONCLUSION:A combined panel of circulating markers including proteins and methylated cfDNA increased discrimination compared with CA19-9 alone for early stage PDAC.
PMCID:10958271
PMID: 38123998
ISSN: 1468-3288
CID: 5825872
Inadequacy of the eighth edition of the American Joint Committee on Cancer pancreatic cancer staging system for invasive carcinoma associated with premalignant lesions in the pancreas: an analysis using the National Cancer Database
Jung, Hye-Sol; Lee, Mirang; Han, Youngmin; Thomas, Alexander S; Yun, Won-Gun; Cho, Young J; Kluger, Michael D; Jang, Jin-Young; Kwon, Wooil
BACKGROUND:Invasive carcinomas arising from premalignant lesions are currently staged by the same criteria as conventional pancreatic ductal adenocarcinoma. METHODS:Clinicopathologic information and survival data were extracted through a thorough search of histology codes from National Cancer Database (2006-2016). A total of 723 patients with invasive intraductal papillary mucinous neoplasm and mucinous cystic neoplasm were analyzed. RESULTS:The median age was 67 years, and 351 patients (48.5%) were male. There were 212 (29.3%), 232 (32.1%), 272 (37.6%), and 7 (1.0%) patients with T1, T2, T3, and T4 classification. Extrapancreatic extension (EPE) was present in 284 (39.3%). Age (HR = 1.504, 95% CI 1.196-1.891), R1 or R2 resection (HR = 1.585, 95% CI 1.175-2.140), and EPE (HR = 1.598, 95% CI 1.209-2.113) were independent prognostic factors for overall survival. Size criteria did not significantly affect survival. The median survival was 115.9 months for patients without EPE, compared to 34.2 months for those with EPE. EPE discriminated survival better than tumor size. DISCUSSION:The T classification of the eighth edition AJCC staging system is not adequate for invasive carcinomas associated with premalignant lesions of the pancreas. They merit a separate, dedicated staging system that uses appropriate prognostic factors.
PMID: 38114399
ISSN: 1477-2574
CID: 5786992
Tumor-selective effects of active RAS inhibition in pancreatic ductal adenocarcinoma
Wasko, Urszula N; Jiang, Jingjing; Curiel-Garcia, Alvaro; Wang, Yingyun; Lee, Bianca; Orlen, Margo; Drizyte-Miller, Kristina; Menard, Marie; Dilly, Julien; Sastra, Stephen A; Palermo, Carmine F; Dalton, Tanner; Hasselluhn, Marie C; Decker-Farrell, Amanda R; Chang, Stephanie; Jiang, Lingyan; Wei, Xing; Yang, Yu C; Helland, Ciara; Courtney, Haley; Gindin, Yevgeniy; Zhao, Ruiping; Kemp, Samantha B; Clendenin, Cynthia; Sor, Rina; Vostrejs, Will; Amparo, Amber A; Hibshman, Priya S; Rees, Matthew G; Ronan, Melissa M; Roth, Jennifer A; Bakir, Basil; Badgley, Michael A; Chabot, John A; Kluger, Michael D; Manji, Gulam A; Quintana, Elsa; Wang, Zhengping; Smith, Jacqueline A M; Holderfield, Matthew; Wildes, David; Aguirre, Andrew J; Der, Channing J; Vonderheide, Robert H; Stanger, Ben Z; Singh, Mallika; Olive, Kenneth P
Broad-spectrum RAS inhibition holds the potential to benefit roughly a quarter of human cancer patients whose tumors are driven by RAS mutations. However, the impact of inhibiting RAS functions in normal tissues is not known. RMC-7977 is a highly selective inhibitor of the active (GTP-bound) forms of KRAS, HRAS, and NRAS, with affinity for both mutant and wild type (WT) variants. As >90% of human pancreatic ductal adenocarcinoma (PDAC) cases are driven by activating mutations in KRAS, we assessed the therapeutic potential of RMC-7977 in a comprehensive range of PDAC models, including human and murine cell lines, human patient-derived organoids, human PDAC explants, subcutaneous and orthotopic cell-line or patient derived xenografts, syngeneic allografts, and genetically engineered mouse models. We observed broad and pronounced anti-tumor activity across these models following direct RAS inhibition at doses and concentrations that were well-tolerated in vivo. Pharmacological analyses revealed divergent responses to RMC-7977 in tumor versus normal tissues. Treated tumors exhibited waves of apoptosis along with sustained proliferative arrest whereas normal tissues underwent only transient decreases in proliferation, with no evidence of apoptosis. Together, these data establish a strong preclinical rationale for the use of broad-spectrum RAS inhibition in the setting of PDAC.
PMCID:10723304
PMID: 38105998
ISSN: 2692-8205
CID: 5786982
Reconsidering the absence of extrapancreatic extension in T staging for pancreatic adenocarcinoma in the AJCC (8th ed) Staging Manual using the National Cancer Database
Lee, Mirang; Thomas, Alexander S; Lee, Seung Yeoun; Cho, Young Jae; Jung, Hye-Sol; Yun, Won-Gun; Han, Youngmin; Jang, Jin-Young; Kluger, Michael D; Kwon, Wooil
PURPOSE:Although the concept of extrapancreatic extension (EPEx) was removed in the eighth edition of the American Joint Committee on Cancer pancreatic cancer staging system, several studies have supported the prognostic significance of EPEx. This study aimed to investigate the significance of EPEx in pancreatic ductal adenocarcinoma (PDAC) using the National Cancer Database (NCDB). METHODS:Data of patients who underwent resection for PDAC between 2006 and 2016 were extracted and analyzed from the NCDB. Cases arising from premalignant lesions, those with metastases, and those treated with neoadjuvant therapy were excluded. RESULTS:Among 37,634 patients, the median overall survival was 23 months and the 5-year survival rate was 22.7%. The EPEx prevalence was the lowest for T1 stage (63.2%) and increased with each T-stage (T2:83.4%, T3:85.8%). The overall survival was better in EPEx-negative patients than in EPEx-positive patients (median 33.7 vs. 21.5 months; p<0.001). When the T-stages were stratified by EPEx, EPEx-positive patients showed worse survival in all T-stages than EPEx-negative patients. Survival was comparable between T1 EPEx-positive and T2 or T3 EPEx-negative patients (p=0.088 and p=0.178, respectively). Furthermore, T2 and T3 EPEx-negative patients had similar survival to each other (p=0.877), and distinctly superior survival compared to T2 and T3 EPEx-positive patients (p<0.001). CONCLUSIONS:EPEx was an important prognostic factor in the overall cohort and in differentiating between T stages. This study strongly suggests that staging systems should reinstate EPEx and apply it to all T-stages, especially in T1, where EPEx was absent in 36% of patients.
PMID: 37848688
ISSN: 1873-4626
CID: 5786972
A blood-based metabolomic signature predictive of risk for pancreatic cancer
Irajizad, Ehsan; Kenney, Ana; Tang, Tiffany; Vykoukal, Jody; Wu, Ranran; Murage, Eunice; Dennison, Jennifer B; Sans, Marta; Long, James P; Loftus, Maureen; Chabot, John A; Kluger, Michael D; Kastrinos, Fay; Brais, Lauren; Babic, Ana; Jajoo, Kunal; Lee, Linda S; Clancy, Thomas E; Ng, Kimmie; Bullock, Andrea; Genkinger, Jeanine M; Maitra, Anirban; Do, Kim-Anh; Yu, Bin; Wolpin, Brian M; Hanash, Sam; Fahrmann, Johannes F
Emerging evidence implicates microbiome involvement in the development of pancreatic cancer (PaCa). Here, we investigate whether increases in circulating microbial-related metabolites associate with PaCa risk by applying metabolomics profiling to 172 sera collected within 5 years prior to PaCa diagnosis and 863 matched non-subject sera from participants in the Prostate, Lung, Colorectal, and Ovarian (PLCO) cohort. We develop a three-marker microbial-related metabolite panel to assess 5-year risk of PaCa. The addition of five non-microbial metabolites further improves 5-year risk prediction of PaCa. The combined metabolite panel complements CA19-9, and individuals with a combined metabolite panel + CA19-9 score in the top 2.5th percentile have absolute 5-year risk estimates of >13%. The risk prediction model based on circulating microbial and non-microbial metabolites provides a potential tool to identify individuals at high risk of PaCa that would benefit from surveillance and/or from potential cancer interception strategies.
PMID: 37729870
ISSN: 2666-3791
CID: 5786962
Associations Between Patient Characteristics and Whipple Procedure Outcomes Before and After Implementation of an Enhanced Recovery After Surgery Protocol
Koerner, Anna S; Thomas, Alexander S; Chabot, John A; Kluger, Michael D; Sugahara, Kazuki N; Schrope, Beth A
PURPOSE:The Enhanced Recovery After Surgery (ERAS) protocol is a multimodal perioperative care bundle aimed to improve pancreatic surgery outcomes. This work evaluates whether a Whipple ERAS protocol can be safely implemented at a quaternary care center. We also aimed to assess if race and socioeconomic factors are associated with disparities in outcomes in patients undergoing a Whipple ERAS protocol. METHODS:A retrospective review identified demographic and clinical data for 458 patients undergoing pancreaticoduodenectomies (PDs) at a single institution from October 2017 to May 2022. Patients were split into two cohorts: pre-ERAS (treated before implementation) and ERAS (treated after). Outcomes included length of stay (LOS), 30-day readmission and mortality rates, and major complications. RESULTS:There were 213 pre-ERAS PD patients, and 245 were managed with an ERAS protocol. More ERAS patients had a BMI > 30 (15.5% vs. 8.0%; p = 0.01) and received neoadjuvant chemotherapy (15.5% vs. 4.2%; p < 0.001). ERAS patients had a higher rate of major complications (57.6% vs. 37.6%; p < 0.001). Medicaid patients did not have more complications or longer LOS compared to non-Medicaid patients. On univariate analysis, race/ethnicity or gender was not significantly associated with a higher rate of major complications or prolonged LOS. CONCLUSION:A Whipple ERAS protocol did not significantly change LOS, readmissions, or 30-day mortality. Rate of overall complications did not significantly change after implementation, but rate of major complications increased. These outcomes were not significantly impacted by race/ethnicity, gender, tumor staging, or insurance status.
PMID: 37165160
ISSN: 1873-4626
CID: 5786942
The role of local treatment including pancreatectomy for pancreatic ductal adenocarcinoma patients with isolated synchronous liver metastasis: Propensity score-matched analyses
Yun, Won-Gun; Han, Youngmin; Lee, Mirang; Cho, Young Jae; Jung, Hye-Sol; Thomas, Alexander S; Kluger, Michael D; Kwon, Wooil; Jang, Jin-Young
BACKGROUND:In an era of more effective chemotherapy for pancreatic ductal adenocarcinoma (PDAC), the paradigm of local treatment is changing. However, the efficacy of local treatment in patients with isolated liver metastasis remains unclear. Therefore, we aimed to evaluate the effectiveness of pancreatectomy ± local treatment for metastasis (cytoreductive surgery) in PDAC patients with isolated synchronous liver metastasis. METHODS:In total, 239 patients with isolated liver metastasis were extracted from Seoul National University Hospital (SNUH). For comparison, another 12 637 patients were extracted from the National Cancer Database (NCDB). Propensity score matching was performed to minimize confounding in both cohorts. Survival analyses stratified by the treatment delivered were performed using Kaplan-Meier estimates and log-rank tests. RESULTS:In the SNUH cohort, the median (interquartile range) survival was 20.5 (13.0-42.0) months for patients who underwent cytoreductive surgery plus chemotherapy versus 12.0 (10.0-18.0) months for those who received chemotherapy alone (P < .001). With the NCDB cohort, the median (interquartile range) survival was 15.6 (8.9-31.2) months for patients who underwent cytoreductive surgery plus chemotherapy versus 7.4 (3.4-13.2) months for those who received chemotherapy alone (P < .001). CONCLUSION/CONCLUSIONS:Patients with isolated synchronous liver metastasis should be considered for cytoreductive surgery in addition to effective chemotherapy.
PMID: 36734117
ISSN: 1868-6982
CID: 5786902